Literature DB >> 11825954

Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load.

Tatsuji Kimura1, Akinori Rokuhara, Yoko Sakamoto, Shintaro Yagi, Eiji Tanaka, Kendo Kiyosawa, Noboru Maki.   

Abstract

A sensitive enzyme immunoassay (EIA) specific for hepatitis B virus core antigen (HBcAg) and hepatitis B e antigen (HBeAg) was developed. We designated the precore/core gene products as hepatitis B virus (HBV) core-related antigens (HBcrAg). In order to detect HBcrAg even in anti-HBc/e antibody-positive specimens, the specimens were pretreated in detergents. The antibodies are inactivated by this pretreatment and, simultaneously, the antigens are released and the epitopes are exposed. The assay demonstrated 71 to 112% recovery using HBcrAg-positive sera. We observed no interference from the tested anticoagulants or blood components. When the cutoff value was tentatively set at 10(3) U/ml, all healthy control (HBsAg/HBV-DNA negative; n = 108) and anti-HCV antibody-positive (n = 59) sera were identified as negative. The assay showed a detection limit of 4 x 10(2) U/ml using recombinant antigen. Detection limits were compared in four serially diluted HBV high-titer sera. The HBcrAg assay demonstrated higher sensitivity than HBV-DNA transcription-mediated amplification (TMA) or HBeAg radio immunoassay (RIA) in the dilution test. HBcrAg concentrations correlated well with HBV-DNA TMA (r = 0.91, n = 29) and in-house real-time detection-PCR (r = 0.93, n = 47) in hepatitis B patients. On HBeAg/anti-HBe antibody seroconversion panels, the HBcrAg concentration changed in accordance with HBV-DNA levels. HBcrAg concentration provides a reflection of HBV virus load equivalent to HBV-DNA level, and the assay therefore offers a simple method for monitoring hepatitis B patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825954      PMCID: PMC153363          DOI: 10.1128/JCM.40.2.439-445.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus.

Authors:  J Salfeld; E Pfaff; M Noah; H Schaller
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.

Authors:  Y F Liaw; C M Chu; I J Su; M J Huang; D Y Lin; C S Chang-Chien
Journal:  Gastroenterology       Date:  1983-02       Impact factor: 22.682

3.  Dane particle-associated hepatitis B e antigen in patients with chronic hepatitis B virus infection and hepatitis B e antibody.

Authors:  G Raimondo; S Recchia; C Lavarini; O Crivelli; M Rizzetto
Journal:  Hepatology       Date:  1982 Jul-Aug       Impact factor: 17.425

4.  Discordance of hepatitis B e antigen/antibody and hepatitis B virus deoxyribonucleic acid in serum. Analysis of 1063 specimens.

Authors:  Y Matsuyama; M Omata; O Yokosuka; F Imazeki; Y Ito; K Okuda
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

5.  Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.

Authors:  S J Hadziyannis; H M Lieberman; G G Karvountzis; D A Shafritz
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

6.  Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique.

Authors:  S Kaneko; S M Feinstone; R H Miller
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

7.  Quantitation of hepatitis B virus (HBV) core antigen in serum in the presence of antibodies to HBV core antigen: comparison with assays of serum HBV DNA, DNA polymerase, and HBV e antigen.

Authors:  R Bredehorst; H von Wulffen; C Granato
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

8.  Immunochemical structure of hepatitis B e antigen in the serum.

Authors:  K Takahashi; A Machida; G Funatsu; M Nomura; S Usuda; S Aoyagi; K Tachibana; H Miyamoto; M Imai; T Nakamura; Y Miyakawa; M Mayumi
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

9.  Relationship between HBeAg and HBV DNA in patients with acute and persistent hepatitis B infection.

Authors:  E J Gowans
Journal:  Med J Aust       Date:  1986-11-03       Impact factor: 7.738

10.  Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe.

Authors:  F Bonino; F Rosina; M Rizzetto; R Rizzi; E Chiaberge; R Tardanico; F Callea; G Verme
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

View more
  48 in total

1.  Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.

Authors:  Akihiro Matsumoto; Shuhei Nishiguchi; Hirayuki Enomoto; Jong-Hon Kang; Yasuhito Tanaka; Noboru Shinkai; Masayuki Kurosaki; Masaru Enomoto; Tatsuo Kanda; Osamu Yokosuka; Hiroshi Yatsuhashi; Shinya Nagaoka; Chiaki Okuse; Tatehiro Kagawa; Tetsuya Mine; Koichi Takaguchi; Satoru Saito; Keisuke Hino; Fusao Ikeda; Shotaro Sakisaka; Daisuke Morihara; Shiho Miyase; Masataka Tsuge; Kazuaki Chayama; Naoki Hiramatsu; Yoshiyuki Suzuki; Kazumoto Murata; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2017-06-20       Impact factor: 7.527

2.  Highly sensitive detection of hepatitis B virus surface antigen by use of a semiautomated immune complex transfer chemiluminescence enzyme immunoassay.

Authors:  Kazuhiko Takeda; Mari Maruki; Takahiro Yamagaito; Machiko Muramatsu; Yasuhiro Sakai; Hiroaki Tobimatsu; Hironori Kobayashi; Yoshiteru Mizuno; Yukio Hamaguchi
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

3.  Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2017-01-05       Impact factor: 6.047

4.  Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy.

Authors:  Masayuki Kurosaki; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Namiki Izumi
Journal:  J Gastroenterol       Date:  2013-03-30       Impact factor: 7.527

5.  Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B.

Authors:  Akihiro Matsumoto
Journal:  J Gastroenterol       Date:  2016-09-24       Impact factor: 7.527

6.  Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.

Authors:  Kazunori Kawaguchi; Masao Honda; Hajime Ohta; Takeshi Terashima; Tetsuro Shimakami; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Takuya Komura; Masashi Unoura; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2017-08-28       Impact factor: 7.527

7.  Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy.

Authors:  Akinori Rokuhara; Akihiro Matsumoto; Eiji Tanaka; Takeji Umemura; Kaname Yoshizawa; Tatsuji Kimura; Noboru Maki; Kendo Kiyosawa
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

8.  New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Akihiro Matsumoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody.

Authors:  Akihiro Matsumoto; Masayasu Imaizumi; Yasuhito Tanaka; Shuhei Nishiguchi; Hiroshi Yatsuhashi; Takehiko Ishida; Kazushige Moriyama; Katsumi Aoyagi; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2016-07-26       Impact factor: 7.527

10.  A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan.

Authors:  Atsunori Kusakabe; Yasuhito Tanaka; Etsuro Orito; Fuminaka Sugauchi; Fuat Kurbanov; Tomoyuki Sakamoto; Noboru Shinkai; Noboru Hirashima; Izumi Hasegawa; Tomoyoshi Ohno; Ryuzo Ueda; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2007-04-26       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.